Neurocrine Biosciences (NBIX) Capital Expenditures Growth (3y) (2013 - 2026)
Neurocrine Biosciences (NBIX) Capital Expenditures Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | -4.39% |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | -11.01% |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | -0.22% |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 34.19% |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | -8.00% |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 4.68% |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | -7.72% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Alkermes | 8.14 Bn | 7.48 Bn | 397.90 Mn | -5.67% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.68% |
| Mar 31, 2026 | 32.64% |
| Dec 31, 2025 | 44.45% |
| Sep 30, 2025 | 35.72% |
| Jun 30, 2025 | -66.69% |
| Mar 31, 2025 | 56.34% |
| Dec 31, 2024 | 61.37% |
| Sep 30, 2024 | -30.12% |
| Jun 30, 2024 | -79.28% |
| Mar 31, 2024 | 382.03% |
| Dec 31, 2023 | -45.34% |
| Sep 30, 2023 | -20.63% |
| Jun 30, 2023 | 25.99% |
| Mar 31, 2023 | -9.14% |
| Dec 31, 2022 | -8.70% |
| Sep 30, 2022 | 7.85% |
| Jun 30, 2022 | -102.74% |
| Mar 31, 2022 | 67.11% |
| Dec 31, 2021 | -27.13% |
| Sep 30, 2021 | 66.91% |